×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
IDYA – ideaya biosciences, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
IDYA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/22
07:49 am
idya
Ideaya Biosciences Inc. (IDYA): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts [Yahoo! Finance]
Low
Report
Ideaya Biosciences Inc. (IDYA): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts [Yahoo! Finance]
11/18
08:50 am
idya
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is now covered by analysts at Stephens. They set an "overweight" rating and a $51.00 price target on the stock.
Low
Report
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is now covered by analysts at Stephens. They set an "overweight" rating and a $51.00 price target on the stock.
11/18
06:10 am
idya
IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer [Yahoo! Finance]
Low
Report
IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer [Yahoo! Finance]
11/18
06:00 am
idya
IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer
Low
Report
IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer
11/12
06:00 am
idya
IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day
Medium
Report
IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day
11/11
06:00 am
idya
Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise
Low
Report
Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise
11/11
06:00 am
idya
Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise
Low
Report
Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise
11/11
06:00 am
idya
IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen
Low
Report
IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
04:23 pm
idya
Form SC 13G/A IDEAYA Biosciences, Inc. Filed by: BIOTECHNOLOGY VALUE FUND L P
Medium
Report
Form SC 13G/A IDEAYA Biosciences, Inc. Filed by: BIOTECHNOLOGY VALUE FUND L P
11/14
03:14 pm
idya
Form SC 13G/A IDEAYA Biosciences, Inc. Filed by: JANUS HENDERSON GROUP PLC
Low
Report
Form SC 13G/A IDEAYA Biosciences, Inc. Filed by: JANUS HENDERSON GROUP PLC
11/14
01:24 pm
idya
Form SC 13G/A IDEAYA Biosciences, Inc. Filed by: PRICE T ROWE ASSOCIATES INC /MD/
Low
Report
Form SC 13G/A IDEAYA Biosciences, Inc. Filed by: PRICE T ROWE ASSOCIATES INC /MD/
11/12
10:33 am
idya
Form SC 13G/A IDEAYA Biosciences, Inc. Filed by: FMR LLC
Low
Report
Form SC 13G/A IDEAYA Biosciences, Inc. Filed by: FMR LLC
11/4
04:06 pm
idya
Form 10-Q IDEAYA Biosciences, Inc. For: Sep 30
Low
Report
Form 10-Q IDEAYA Biosciences, Inc. For: Sep 30
11/4
06:04 am
idya
Form 8-K IDEAYA Biosciences, Inc. For: Nov 04
Medium
Report
Form 8-K IDEAYA Biosciences, Inc. For: Nov 04
10/25
06:05 am
idya
Form 8-K IDEAYA Biosciences, Inc. For: Oct 25
Low
Report
Form 8-K IDEAYA Biosciences, Inc. For: Oct 25
10/4
04:02 pm
idya
Form 8-K IDEAYA Biosciences, Inc. For: Oct 04
Low
Report
Form 8-K IDEAYA Biosciences, Inc. For: Oct 04
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/13
Q3/2019 9/30/2019 EPS -0.540 ZacksConsensus -0.670 ActVsEst 0.130 - Beat
47.4%
12/18 Form 8-K IDEAYA Biosciences, Inc. For: Dec 17 14.3%
3/24 Q4/2019 12/31/2019 EPS -0.530 ZacksConsensus -0.570 ActVsEst 0.040 - Beat 12.0%
12/19 Form 3 IDEAYA Biosciences, Inc. For: Dec 17 Filed by: YARNO WENDY L 11.8%
4/7 Form 8-K IDEAYA Biosciences, Inc. For: Apr 06 10.9%
9/9 IDEAYA Biosciences (NASDAQ: IDYA) is now covered by analysts at Robert W. Baird. They set an "outperform" rating on the stock. 9.9%
11/19 IDEAYA Biosciences (NASDAQ: IDYA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.75 price target on the stock. 8.9%
4/6 IDEAYA Biosciences (NASDAQ: IDYA) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. 8.5%
10/31 IDEAYA Biosciences Reports End-of-Phase 1 Meeting with FDA for IDE196 Confirms Acceptability of Single-Arm Trial Design for Potential Phase 2 Registration-Enabling Study in Metastatic Uveal Melanoma 7.9%
1/10 IDEAYA Biosciences and Boston Children's Hospital Collaborate on Preclinical Evaluation of IDE196 for Sturge Weber Syndrome - a Rare Disease Associated with Genetic Mutation of GNAQ 7.5%
12/18 Form 8-K IDEAYA Biosciences, Inc. For: Dec 17 14.3%
3/24 Q4/2019 12/31/2019 EPS -0.530 ZacksConsensus -0.570 ActVsEst 0.040 - Beat 12.0%
12/19 Form 3 IDEAYA Biosciences, Inc. For: Dec 17 Filed by: YARNO WENDY L 11.8%
4/7 Form 8-K IDEAYA Biosciences, Inc. For: Apr 06 10.9%
9/9 IDEAYA Biosciences (NASDAQ: IDYA) is now covered by analysts at Robert W. Baird. They set an "outperform" rating on the stock. 9.9%
11/19 IDEAYA Biosciences (NASDAQ: IDYA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.75 price target on the stock. 8.9%
4/6 IDEAYA Biosciences (NASDAQ: IDYA) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. 8.5%
10/31 IDEAYA Biosciences Reports End-of-Phase 1 Meeting with FDA for IDE196 Confirms Acceptability of Single-Arm Trial Design for Potential Phase 2 Registration-Enabling Study in Metastatic Uveal Melanoma 7.9%
1/10 IDEAYA Biosciences and Boston Children's Hospital Collaborate on Preclinical Evaluation of IDE196 for Sturge Weber Syndrome - a Rare Disease Associated with Genetic Mutation of GNAQ 7.5%
TOP News Decliners
11/20
Phase 1/2 Clinical Trial Data for IDE196 Presented at Society for Melanoma Research Congress
-23.8%
3/11 IDEAYA Biosciences and Cancer Research UK Announce Expanded Research Collaboration for PARG, a DDR-Based Synthetic Lethality Target, Evaluating DNA Replication Vulnerabilities -20.3%
5/22 Form CERT IDEAYA Biosciences, Inc. -20.1%
8/1 Form 4 IDEAYA Biosciences, Inc. For: Jul 30 Filed by: Hata Yujiro S -11.6%
10/17 IDEAYA Biosciences (NASDAQ: IDYA) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $17.00 price target on the stock. -10.7%
1/16 IDEAYA Biosciences (NASDAQ: IDYA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.5%
4/1 IDEAYA Biosciences (NASDAQ: IDYA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.0%
1/29 IDEAYA Biosciences (NASDAQ: IDYA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $9.75 price target on the stock. -6.1%
2/6 Form SC 13G IDEAYA Biosciences, Inc. Filed by: CANAAN X L.P. -4.9%
11/13 Form 8-K IDEAYA Biosciences, Inc. For: Nov 13 -4.7%
3/11 IDEAYA Biosciences and Cancer Research UK Announce Expanded Research Collaboration for PARG, a DDR-Based Synthetic Lethality Target, Evaluating DNA Replication Vulnerabilities -20.3%
5/22 Form CERT IDEAYA Biosciences, Inc. -20.1%
8/1 Form 4 IDEAYA Biosciences, Inc. For: Jul 30 Filed by: Hata Yujiro S -11.6%
10/17 IDEAYA Biosciences (NASDAQ: IDYA) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $17.00 price target on the stock. -10.7%
1/16 IDEAYA Biosciences (NASDAQ: IDYA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.5%
4/1 IDEAYA Biosciences (NASDAQ: IDYA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.0%
1/29 IDEAYA Biosciences (NASDAQ: IDYA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $9.75 price target on the stock. -6.1%
2/6 Form SC 13G IDEAYA Biosciences, Inc. Filed by: CANAAN X L.P. -4.9%
11/13 Form 8-K IDEAYA Biosciences, Inc. For: Nov 13 -4.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: